Atea Pharmaceuticals and Galera Therapeutics plunge after respective studies failed to meet primary endpoints Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Energous (WATT) up 29% after announcing that its 900MHz 1W Active Energy Harvesting transmitter technology has received U.S. Federal Communications Commission Part 15 grant of equipment authorization for wireless power transfer at any distance
- Walmart (WMT) up 2% after Goldman Sachs analyst Kate McShane added the stock to the firm's Conviction List
- Merck (MRK) up 2% after Atea Pharmaceuticals (AVIR) reported that AT-527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate Covid compared to placebo
- GameStop (GME) up 1% after the Wall Street Journal reported that following the trading frenzy in shares of GameStop earlier this year, regulators are considering whether "game-like" brokerage apps are encouraging investors to trade too much
UP AFTER EARNINGS -
- Steel Dynamics (STLD) up 2%
DOWN AFTER EARNINGS -
- Procter & Gamble (PG) down 2%
LOWER -
- Atea Pharmaceuticals (AVIR) down 73% after reporting that the global Phase 2 MOONSONG trial evaluating AT-527 in the outpatient setting did not meet the primary endpoint of reduction from baseline in the amount of SARS-CoV-2 virus in patients with mild or moderate COVID-19 compared to placebo in the overall study population
- Galera Therapeutics (GRTX) down 71% after announcing its Phase 3 ROMAN trial of avasopasem manganese for severe oral mucositis in patients with locally advanced head and neck cancer undergoing standard-of-care radiotherapy did not meet its primary endpoint
- dLocal (DLO) down 7% after filing to sell 16M shares of common stock and reporting preliminary Q3 revenue
Symbols:
WATT WMT MRK GME STLD PG - $142.31 /
-2.185 (-1.51%)
AVIR GRTX DLO Keywords: Fly Intel, Wall Street, Top Stories, Stocks